GammaTile Therapy Offers Patients a Proven Option to Slow Brain Tumor Progression, Delay Recurrence and Avoid Additional Trips to the Hospital for Radiation Therapy
TEMPE, Ariz.–(BUSINESS WIRE)–GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners. Funds from the round will support the expanded commercialization of GammaTile® Therapy, an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.
“We are excited that this funding will support our efforts to further expand access to STaRT, allowing even more patients to benefit from this targeted treatment.”